The notion for combining entero-pancreatic hormone-based therapies for obesity treatment is supported by the efficacy of bariatric surgery on WL, an intervention leading to increased postprandial levels of multiple entero-pancreatic hormones [31, 32]
A large-scale genome-wide association study published in Nature in April 2026, conducted by 23andMe researchers using data from 27,885 GLP-1 medication users, identified a specific variant in the GLP1R gene the gene that encodes the primary receptor these drugs target associated with differential weight loss efficacy
Nilsen, J., Sandlie, I., Roopenian, D
These medicines include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 agonist